Randomized, open-label study of oral ABL001 versus bosutinib in patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors

Type of Cancer
Leukemia

Sponsor
Novartis

Protocol Number
Novartis CABL001A2301

To Learn More Call
(201)-510-0950